Fall from grace

On May 13, Indian off-patent drugs producer Ranbaxy Laboratories agreed to pay $500 million to settle US government charges of fraud at its Indian factories. Investigators found, thanks to a former Ranbaxy employee who blew the whistle, that in the mid-to-late 2000s, company executives had extensively fabricated test data on generics destined for the US and suppressed unfavourable results.

Read Full Story>>